SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vertex Pharmaceuticals (VRTX)
VRTX 434.51+2.9%2:33 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (541)10/10/2001 12:41:33 PM
From: keokalani'nui  Read Replies (1) of 1169
 
P38. Boehringer has several abstracts [671, 371, 367, 1891] at ACR on its anti-p38 candidate, one in 24 humans given a inflammation challenge [671]. Can't tell how it stacks up against competition, but substantial cytokine inhibition going on.

Also, Nereus Pharma has a small mol anti-TNFa and anti-IL-1 synthesis inhibitor [376] that may be interesting to watch. They clearly hope this will be their ticket to IPO.

Wilder
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News